Scott T. Moe
Scott T. Moe publishes mostly in Molecular Biology, Cellular and Molecular Neuroscience and Oncology, on topics such as Monoclonal and Polyclonal Antibodies Research, Cancer Research and Treatments and Pharmacological Receptor Mechanisms and Effects.
- World rank
- #5,800,926 of 7,710,434 ranked researchers
- Rank in United States
- #1,433,086 of 1,627,098
- Works
- 32
- Citations
- 528
- Citations per work
- 16.5
What does Scott T. Moe research?
Scott T. Moe's work is mostly in Biochemistry, Genetics and Molecular Biology (30%), Medicine (20%), Neuroscience (14%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Life Sciences1444.4%
- Everything else928.9%
- Health Sciences620.0%
- Medicine620.0%
- Physical Sciences26.7%
- Chemistry26.7%
- 1Molecular Biology23% of their works
- 2Cellular and Molecular Neuroscience14% of their works
- 3Oncology12% of their works
- 4Radiology, Nuclear Medicine and Imaging8% of their works
- 5Organic Chemistry7% of their works
- 6Biotechnology7% of their works
Research topics
- Monoclonal and Polyclonal Antibodies Research
- Cancer Research and Treatments
- Pharmacological Receptor Mechanisms and Effects
- Neuroscience and Neuropharmacology Research
- CAR-T cell therapy research
- Neuropeptides and Animal Physiology
- Botulinum Toxin and Related Neurological Disorders
- Glycosylation and Glycoproteins Research
Which keywords describe Scott T. Moe's research?
The keywords of their largest research topics: Immunotherapy, Tumor Regression, Glycosylation, Neurological Disorders, Fc Receptors, Therapeutic Antibodies, Bacterial Therapy and CAR T Cells.
- Glycans
- Receptors
- Neuropeptides
- Tumor Targeting
- Sigma-1 Receptor
- Chimeric Antigen Receptor
- CAR T Cells
- Therapeutic Antibodies
- Neurological Disorders
- Tumor Regression
- Immunotherapy
- Glycosylation
- Fc Receptors
- Bacterial Therapy
- Chaperone
- Neurotransmission
- Synaptic Plasticity
- Botulinum Toxin
- Neurotoxins
- Cancer
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 20 words, with their numbers
- Immunotherapy122 topics
- Tumor Regression122 topics
- Glycosylation102 topics
- Neurological Disorders102 topics
- Fc Receptors71 topic
- Therapeutic Antibodies71 topic
- Bacterial Therapy61 topic
- CAR T Cells61 topic
- Chaperone61 topic
- Chimeric Antigen Receptor61 topic
- Neurotransmission61 topic
- Sigma-1 Receptor61 topic
- Synaptic Plasticity61 topic
- Tumor Targeting61 topic
- Botulinum Toxin41 topic
- Neuropeptides41 topic
- Neurotoxins41 topic
- Receptors41 topic
- Cancer31 topic
- Glycans31 topic
Where does Scott T. Moe work?
Scott T. Moe's main affiliation in the publication record is Minerva Biotechnologies (United States), United States.
How many publications and citations does Scott T. Moe have?
OpenAlex counts 32 works and 528 citations for Scott T. Moe, an h-index of 13, ranking #5,800,926 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Scott T. Moe. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.